Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 28 of 58, showing 10 Applications out of 576 total, starting on record 271, ending on 280

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

271.

ECCT/21/02/01   PTSD 102 TONIX
    A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants with PTSD Taken Daily at Bedtime (Protocol No. TNX-CY-P308).   
Principal Investigator(s)
1. Prof. Lukoye Atwoli
Site(s) in Kenya
1. Moi Teaching and Referral Hospital/Moi University (Uasin Gishu county)
2. KEMRI Nairobi (Nairobi City county)
3. Aga Khan University Hospital (Nairobi City county)
 
16-06-2021 View

272.

ECCT/21/03/03   PrEP My Way
    A Novel PrEP Delivery System to Meet the Needs of Young African Women   
Principal Investigator(s)
1. Prof. Elizabet Ann Bukusi
Site(s) in Kenya
Kisumu
 
06-07-2021 View

273.

ECCT/20/12/02   MERS-201
    Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy Volunteers   
Principal Investigator(s)
1. Bernhards Ogutu
2. Josphat Kosgei
Site(s) in Kenya
1. Ahero Clinical Trials Unit (Kisumu county)
2. Kenya Medical Research Institute/Walter Reed Project (KEMRI/WRP) (Kericho county)
 
15-07-2021 View

274.

ECCT/21/05/03   Adapt Out COVID
    Adaptive Platform Treatment trial for Outpatients with COVID-19   
Principal Investigator(s)
1. Kawango Agot
Site(s) in Kenya
1. Kenya Impact and Research Development Organization (K-IRDO) (Kisumu county)
2. KEMRI WALTER REED (Kericho county)
3. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (Uasin Gishu county)
4. Kenya Medical Research Institute (Kisumu county)
 
28-07-2021 View

275.

ECCT/21/06/04   VAT00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted  Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of ageand older   
Principal Investigator(s)
1. Lucas Otieno
Site(s) in Kenya
1. KEMRI-UAMRD-A/K, Kombewa Clinical Research Center (Kisumu county)
2. Kenya Medical Research Institute (Kisumu county)
3. KEMRI/Walter Reed Project Research Center (Kericho county)
4. Ganjoni Clinic (Mombasa county)
5. KEMRI/CCR Partners in Health R&D (PHRD) (Nairobi City county)
6. Kenya Medical Research Institute (Murang\'a county)
7. Moi University Clinical Research Centre (Uasin Gishu county)
8. Aga Khan University Hospital (Nairobi City county)
9. KEMRI CCR-Butere County Hospital Site (Kakamega county)
 
02-08-2021 View

276.

ECCT/21/06/02   VAT00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older.   
Principal Investigator(s)
1. Videlis Nduba
Site(s) in Kenya
1. Kenya Medical Research Institute (Nairobi City county)
2. KEMRI/Walter Reed Project Research Center-Kericho (Kericho county)
3. KEMRI-UAMRD-A/K, Kombewa Clinical Research Center-Kisumu (Kisumu county)
4. Ganjoni Clinic – Mombasa (Mombasa county)
5. KEMRI/CCR Partners in Health R&D (PHRD)-Thika (Kiambu county)
6. Kenya Medical Research Institute (Kisumu county)
7. Moi University Clinical Research Centre (Uasin Gishu county)
8. Aga Khan University Hospital-Nairobi (Nairobi City county)
9. KEMRI CCR-Butere County Hospital Site- Butere (Kakamega county)
 
02-08-2021 View

277.

ECCT/21/06/03   VAT00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the   efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein   Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age   and older   
Principal Investigator(s)
1. PROF.ELIZABETH ANNE BUKUSI
2. MARICIANAH A ONONO
Site(s) in Kenya
1. Kenya Medical Research Institute (KEMRI) Center for Microbiology Research - Research Care and Training Program (KEMRI CMRRCTP) (Kisumu county)
2. KEMRI CCRButere County Hospital Site (Kakamega county)
3. Aga Khan University Hospital (Nairobi City county)
4. Kenya Medical Research Institute CGHR (Kisumu county)
5. Kenya Medical Research Institute (Nairobi City county)
6. KEMRI/CCR Partners in Health R&D (PHRD (Kiambu county)
7. KAVI-Institute of Clinical Research, University of Nairobi (Nairobi City county)
8. Ganjoni Clinic (Mombasa county)
9. KEMRI-UAMRD-A/K, Kombewa Clinical Research Cente (Kisumu county)
10. KEMRI/Walter Reed Project Research Center (Kericho county)
 
02-08-2021 View

278.

21/06/16   VAT00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older   
Principal Investigator(s)
1. Fredrick Sawe
Site(s) in Kenya
1. Kenya Medical Research Institute, Kisumu Clinical Reseach Site (Kisumu county)
2. KEMRI/Walter Reed Project - Clinical Research Center, Kericho (Kericho county)
3. Ganjoni Clinic - University of Washington/University of Nairobi, Mombasa (Mombasa county)
4. Partners in Health Research and Development, Thika (Kiambu county)
5. KARGENO RESEARCH AND POLICY HUB (Kisumu county)
6. The Centre for Respiratory Diseases Research (CRDR), Kenya Medical Research Institute (KEMRI) (Nairobi City county)
7. KEMRI-USAMRD-A/K, Kombewa Clinical Research Center (Kisumu county)
8. Moi University Clinical Research Centre (MUCRC), Chandaria Cancer and Chronic Diseases Center (CCCDC) (Uasin Gishu county)
9. Aga Khan University Hospital (Nairobi City county)
10. KEMRI CCR-Butere County Hospital Site (Kakamega county)
 
02-08-2021 View

279.

ECCT/21/06/05   VAT00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of ageand older   
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
KEMRI-CCR-PHRD THIKA PROJECT
 
02-08-2021 View

280.

ECCT/21/05/02   BFTAF Elderly Switch Study
    Switching virally suppressed HIV-1 infected elderly adults (age ≥ 60 years) without prior confirmed virological failure from current anti-retroviral regimen to bictegravir, emtricitabine and tenofovir alafenamide (B/F/TAF)   
Principal Investigator(s)
1. Loice Achieng Ombajo
Site(s) in Kenya
1. Kenyatta National Hospital (Nairobi City county)
2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
 
04-08-2021 View